^
Association details:
| Biomarker: | PPM1D mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug Class: | CD19-targeted CAR-T immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma
Published date:
12/13/2023
Excerpt:
While the prevalent treatment outcome within the PPM1Dwt subgroup was complete remission (56%), the majority of patients within the PPM1Dmut subgroup had only partial remission (60%). Median progression-free survival (PFS) was 3 vs. 12 months (p = 0.07) and median overall survival (OS) was 5 vs. 37 months (p = 0.004) for the PPM1Dmut and PPM1Dwt cohort, respectively. Our data suggest that the occurrence of PPM1D mutations in the context of CH may predict worse outcomes after CD19-targeted CAR T-cell therapy in patients with r/r DLBCL.
DOI:
10.3390/curroncol30120762
